tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Zevra Therapeutics price target lowered to $24 from $25 at Canaccord
PremiumThe FlyZevra Therapeutics price target lowered to $24 from $25 at Canaccord
17d ago
Zevra Therapeutics: Strong Q3 Performance and Promising Pipeline Justify Buy Rating
Premium
Ratings
Zevra Therapeutics: Strong Q3 Performance and Promising Pipeline Justify Buy Rating
17d ago
Zevra Therapeutics Reports Strong Q3 2025 Revenue Growth
Premium
Company Announcements
Zevra Therapeutics Reports Strong Q3 2025 Revenue Growth
17d ago
Zevra Therapeutics rumor highlighted in Betaville blog
PremiumThe FlyZevra Therapeutics rumor highlighted in Betaville blog
3M ago
Zevra Therapeutics: Strong Buy Rating Amid Impressive Q2 Results and Strategic Growth Potential
Premium
Ratings
Zevra Therapeutics: Strong Buy Rating Amid Impressive Q2 Results and Strategic Growth Potential
3M ago
Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability
Premium
Company Announcements
Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability
3M ago
Zevra Therapeutics Reports Strong Q2 2025 Results
PremiumCompany AnnouncementsZevra Therapeutics Reports Strong Q2 2025 Results
3M ago
Zevra Therapeutics reports Q2 EPS $1.21, consensus $1.38
Premium
The Fly
Zevra Therapeutics reports Q2 EPS $1.21, consensus $1.38
3M ago
Zevra Therapeutics Inc options imply 12.4% move in share price post-earnings
Premium
The Fly
Zevra Therapeutics Inc options imply 12.4% move in share price post-earnings
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100